Cooley LLP is a market leader in life sciences and technology offerings, including for a growing number of European, Asian and Latin American issuers. A new office in Miami has increased its connection to the Latin American market. In 2023, it continued to work on a series of IPOs and follow-on offerings by issuers in Europe and Asia. The firm has a wide-ranging and impressive client base from start-ups to growth businesses and established public companies. It is also close to key financial institutions. A force in equity offerings, it has a further presence in equity-linked transactions. San Diego-based Charlie Kim heads the capital markets team alongside David Peinsipp in San Francisco. New York’s Div Gupta and Richard Segal are also leading names.
Key clients
- Abivax S.A.
- Addex Therapeutics SA
- Ambrx Biopharma
- Autolus Therapeutics plc
- Bicycle Therapeutics plc
- Cowen and Company
- Exscientia plc
- Faron Pharmaceuticals Oy
- Gamida Cell Ltd.
- Goldman Sachs & Co. LLC
- Gracell Biotechnologies
- Immunocore Limited
- J.P. Morgan Securities LLC
- Jefferies LLC
- Lava Therapeutics
- Legend Biotech Corporation
- Molecular Partners AG
- Morgan Stanley & Co.
- Oculis SA
- Structure Therapeutics Inc.
Work highlights
- Advised the underwriters on argenx SE’s $1.2bn follow-on offering.
- Represented Abivax in its $235.8m IPO.
- Advised Structure Therapeutics on its $185.3m IPO.
Practice head
The lawyer(s) leading their teams.
Charlie Kim, David Peinsipp